IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
Tuesday, September 26, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
Price reaction · baseline $27.19 (2023-09-25 close) · hit after-hours · 2 other IDYA headline(s) in the window, move may be shared
day 0 close
-2.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma
Full Press Release Details
IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations.